Feature | March 24, 2014

Sorin Acquires Oscor’s CRM Lead Business for MRI Compatible Standard Systems

Acquisition will allow Sorin to respond better to the rapidly changing market conditions, requiring high-quality value-driven MRI compatible standard systems

March 24, 2014 — Sorin Group has purchased Oscor Inc. lead business, including a lead manufacturing facility in the Dominican Republic for a value of approximately $20 million.

Oscor, headquartered in Tampa Fla., is one of the largest independent players in the development and manufacture of cardiac leads and catheters. With more than 400 employees and manufacturing facilities in the United States and the Dominican Republic, Oscor sells its products both to end-customers and to leading medical device companies, including Sorin Group, on an original equipment manufacturer (OEM) basis.

Under this agreement, Sorin Group acquires: 1) Oscor-branded and OEM for Sorin bradycardia lead business; 2) design files and development resources which will be the foundation for the development of magnetic resonance imaging (MRI) compatible tachycardia and left ventricular leads; and 3) one of Oscor’s fully equipped lead manufacturing facilitues, ISO certified and FDA registered, based in the Dominican Republic.

Sorin Group expects this acquisition will generate additional revenues from Oscor’s existing lead business and consolidate its MRI-compatible brady leads that are currently produced by Oscor. In addition, this agreement represents an opportunity for further co-operative development with Oscor of brady and tachy leads that will accommodate upcoming market requirements for MRI.

The transaction is subject to customary closing conditions.

For more information: www.sorin.com

Related Content

CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle or a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe
News | EP Lab| September 27, 2016
In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement...
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
don woodlock, GE Healthcare, EP CVIS, electrophyiology
Sponsored Content | Webinar | Cardiac PACS| September 16, 2016
Cardiac rhythm management (CRM) data is becoming increasingly important in the management of patients with implantabl
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
Sponsored Content | Videos | Heart Failure| September 02, 2016
The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by res
Respicardia, Remede, pacemaker for sleep apnea, central sleep apnea treatment

The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with central sleep apnea.

News | Heart Failure| September 02, 2016
September 2, 2016 — Results from an international, randomized study show that an implanted nerve stimulator significa
Overlay Init